eXoZymes Inc. (EXOZ)
Nasdaq: EXOZ · Biological Products, (No Diagnostic Substances) · Monrovia, CA · filing with the SEC since 2024
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 30, 2026 | Mar 31, 2025 | · |
| Revenue | · | · | 70,069 |
| Research and development | 3,706,991 | 1,868,766 | 527,480 |
| General and administrative | 6,009,480 | 4,063,339 | 1,338,811 |
| Total costs and expenses | 9,716,471 | 5,932,105 | 1,866,291 |
| Operating income | -9,716,471 | -5,932,105 | -1,796,222 |
| Interest income (expense), net | 363,786 | 77,612 | 100 |
| Other income (expense), net | 88,746 | -6,834 | · |
| Income before income taxes | -9,263,939 | -5,861,335 | -1,996,122 |
| Income tax expense | -105,205 | · | 42,267 |
| Net income | -9,158,734 | -5,861,335 | -2,038,389 |
| Earnings per share, basic | -1.09 | -0.89 | -0.33 |
| Earnings per share, diluted | -1.09 | -0.89 | -0.33 |
| Weighted average shares, basic | 8,381,444 | 6,563,255 | 6,250,002 |
| Weighted average shares, diluted | 8,381,444 | 6,563,255 | 6,250,002 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:OperatingCostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding